Eton Pharmaceuticals’ (ETON) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Eton Pharmaceuticals (NASDAQ:ETON) in a research report released on Wednesday,Benzinga reports. The firm currently has a $33.00 price objective on the stock.

Several other research firms also recently commented on ETON. Craig Hallum increased their target price on Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. B. Riley initiated coverage on Eton Pharmaceuticals in a research report on Friday, January 10th. They issued a “buy” rating and a $21.00 target price for the company.

Eton Pharmaceuticals Trading Up 1.4 %

Eton Pharmaceuticals stock opened at $14.88 on Wednesday. The company has a market capitalization of $387.64 million, a PE ratio of -67.64 and a beta of 1.37. Eton Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $18.41. The stock has a 50-day moving average price of $15.51 and a two-hundred day moving average price of $11.45.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Tuesday, March 18th. The company reported ($0.02) EPS for the quarter, meeting the consensus estimate of ($0.02). The firm had revenue of $11.65 million during the quarter, compared to the consensus estimate of $10.53 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. As a group, analysts predict that Eton Pharmaceuticals will post -0.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Jefferies Financial Group Inc. bought a new position in shares of Eton Pharmaceuticals during the fourth quarter worth about $133,000. Two Sigma Advisers LP acquired a new stake in Eton Pharmaceuticals during the fourth quarter worth approximately $662,000. Two Sigma Investments LP acquired a new stake in Eton Pharmaceuticals during the fourth quarter worth approximately $1,498,000. Point72 Asia Singapore Pte. Ltd. grew its stake in Eton Pharmaceuticals by 18.3% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company’s stock worth $141,000 after purchasing an additional 1,634 shares during the period. Finally, Parkman Healthcare Partners LLC grew its stake in Eton Pharmaceuticals by 6.4% during the fourth quarter. Parkman Healthcare Partners LLC now owns 276,890 shares of the company’s stock worth $3,688,000 after purchasing an additional 16,664 shares during the period. 27.86% of the stock is currently owned by institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.